Home › Companies › Immunome, Inc. › 2025-2026

Immunome, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Immunome, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
220Asset managers
1,771Fund votes
2026-06-09Meeting date

Proxy season: 2025-2026

Explore Immunome, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Immunome, Inc.

These tallies are Immunome, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Immunome, Inc. — official shareholder meeting results, meeting held 2026-06-09
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: James Boylan	70,209,570	--	--	22,171,996	11,768,578	Majority: yes
Elect Director: Sandra Swain, M.D.	92,157,301	--	--	224,265	11,768,578	Majority: yes
Elect Director: Philip Wagenheim	92,162,632	--	--	218,934	11,768,578	Majority: yes
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending Decemb	104,100,900	27,134	22,110	--	--	Majority: yes
Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement	90,908,436	1,442,116	31,014	--	11,768,578	Majority: yes

Source: Immunome, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.

How asset managers voted at the Immunome, Inc. 2025-2026 meeting

Each item below shows how the 220 asset managers that disclosed a Immunome, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Immunome, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 90,908,436AGAINST: 1,442,116

Immunome, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement”): 90,908,436 for, 1,442,116 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 113,171,396 outstanding shares: 80% for, 1% against (82% of the company cast a for/against vote).

The 220 asset managers below cast 99.3% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 99.3%

FOR: 99.3%AGAINST: 0.6%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers.” at Immunome, Inc., 2025-2026
Asset manager	For	Against	Vote
T. Rowe Price	32,472,236	0	For
Fidelity	26,500,573	0	For
Vanguard	9,041,004	4	For
Redmile Group, LLC	5,345,485	0	For
BlackRock	5,169,727	6,465	For
PRIMECAP MANAGEMENT CO/CA/	4,554,625	0	For
State Street	3,905,322	2,028	For
Wellington	3,894,903	0	For
PRIMECAP Odyssey Funds	3,867,541	0	For
Enavate Sciences GP, LLC	3,613,799	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,494,110	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	2,443,772	0	For
Charles Schwab	1,706,548	0	For
Polar Capital Holdings Plc	1,606,780	0	For
Janus Henderson	1,412,778	0	For
Woodline Partners LP	1,195,499	0	For
JPMorgan	1,123,081	0	For
BNP Paribas Asset Management Holding S.A.	1,097,836	0	For
SILVERARC CAPITAL MANAGEMENT, LLC	981,262	0	For
PRINCIPAL GLOBAL INVESTORS	911,883	0	For
Sofinnova Investments, Inc.	836,121	0	For
NAN FUNG TRINITY (HK) Ltd	714,553	0	For
DRIEHAUS MUTUAL FUNDS	622,369	0	For
Principal	565,036	0	For
Northern Trust	545,530	7,585	For

Showing the 25 largest of 220 asset managers. See all 220 in the interactive database.

2. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.3% fund support · no official result

ONE YEAR 75%1 YEAR 25%

The 212 asset managers below cast 99.3% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR: 0.1%AGAINST: 0.0%ABSTAIN: 0.0%ONE YEAR: 74.9%1 YEAR: 25.0%1.0: 0.0%THREE YEARS: 0.0%3 YEARS: 0.0%1-YEAR: 0.0%NOT VOTED: 0.0%2.0: 0.0%

Largest asset managers voting on “To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation o” at Immunome, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
T. Rowe Price	0	0	0	0	One Year
Fidelity	0	0	0	0	One Year
Vanguard	0	0	0	0	One Year
Redmile Group, LLC	0	0	0	0	1 Year
BlackRock	0	0	0	0	1 Year
PRIMECAP MANAGEMENT CO/CA/	0	0	0	0	1 Year
State Street	0	0	0	0	One Year
Wellington	0	0	0	0	1 Year
PRIMECAP Odyssey Funds	0	0	0	0	1 Year
Enavate Sciences GP, LLC	0	0	0	0	1 Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
DRIEHAUS CAPITAL MANAGEMENT LLC	0	0	0	0	One Year
Charles Schwab	0	0	0	0	1 Year
Polar Capital Holdings Plc	0	0	0	0	One Year
Janus Henderson	0	0	0	0	One Year
JPMorgan	0	0	0	0	One Year
BNP Paribas Asset Management Holding S.A.	0	0	0	0	One Year
SILVERARC CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
PRINCIPAL GLOBAL INVESTORS	0	0	0	0	One Year
Sofinnova Investments, Inc.	0	0	0	0	One Year
NAN FUNG TRINITY (HK) Ltd	0	0	0	0	One Year
DRIEHAUS MUTUAL FUNDS	0	0	0	0	One Year
Principal	0	0	0	0	One Year
Northern Trust	0	0	0	0	1 Year
Candriam S.C.A.	0	0	0	0	One Year

Showing the 25 largest of 212 asset managers. See all 212 in the interactive database.

3. To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: James Boylan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%

FOR: 70,209,570WITHHELD: 22,171,996

Immunome, Inc.’s own tally for this item (“Elect Director: James Boylan”): 70,209,570 for, 22,171,996 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 113,171,396 outstanding shares: 62% for, 20% withheld (82% of the company cast a for/withheld vote).

The 67 asset managers below cast 100% of the shares they voted on this item FOR (42,977,375 for, 0 against).

FOR 89%11%

FOR: 42,977,375 (89.4%)ABSTAIN: 5,116,166 (10.6%)

Largest asset managers voting on “To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until” at Immunome, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	13,126,857	0	For
Fidelity	10,977,814	0	For
Vanguard	8,172,089	4,730	For
PRIMECAP Odyssey Funds	3,867,541	0	For
BlackRock	3,035,715	0	For
State Street	4,832	2,333,467	Abstain
JPMorgan	1,123,081	0	For
Charles Schwab	853,198	0	For
DRIEHAUS MUTUAL FUNDS	0	622,369	Abstain
Principal	0	565,036	Abstain
JANUS INVESTMENT FUND	352,024	0	For
Tema ETF Trust	301,042	0	For
TIAA	295,345	0	For
Equitable	188,889	61,830	For
First Trust	0	238,199	Abstain
Hartford	133,744	0	For
RBB FUND, INC.	0	132,949	Abstain
Lincoln Financial	9,953	113,213	Abstain
Columbia Threadneedle	121,028	0	For
Victory Capital	1,553	107,919	Abstain
Northwestern Mutual	108,857	0	For
QUANTITATIVE MASTER SERIES LLC	108,308	0	For
TRUST FOR PROFESSIONAL MANAGERS	0	101,877	Abstain
OPTIMUM FUND TRUST	0	97,140	Abstain
John Hancock	63,851	26,212	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

4. To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: Philip Wagenheim

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 92,162,632WITHHELD: 218,934

Immunome, Inc.’s own tally for this item (“Elect Director: Philip Wagenheim”): 92,162,632 for, 218,934 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 113,171,396 outstanding shares: 81% for, 0.2% withheld (82% of the company cast a for/withheld vote).

The 67 asset managers below cast 100% of the shares they voted on this item FOR (48,078,807 for, 0 against).

FOR 99.9%

FOR: 48,078,807 (100.0%)ABSTAIN: 14,734 (0.0%)

Largest asset managers voting on “To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until” at Immunome, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	13,126,857	0	For
Fidelity	10,977,814	0	For
Vanguard	8,176,818	1	For
PRIMECAP Odyssey Funds	3,867,541	0	For
BlackRock	3,035,715	0	For
State Street	2,338,299	0	For
JPMorgan	1,123,081	0	For
Charles Schwab	853,198	0	For
DRIEHAUS MUTUAL FUNDS	622,369	0	For
Principal	565,036	0	For
JANUS INVESTMENT FUND	352,024	0	For
Tema ETF Trust	301,042	0	For
TIAA	295,345	0	For
Equitable	250,719	0	For
First Trust	238,199	0	For
Hartford	133,744	0	For
RBB FUND, INC.	132,949	0	For
Lincoln Financial	123,166	0	For
Columbia Threadneedle	121,028	0	For
Victory Capital	109,472	0	For
Northwestern Mutual	108,857	0	For
QUANTITATIVE MASTER SERIES LLC	108,308	0	For
TRUST FOR PROFESSIONAL MANAGERS	101,877	0	For
OPTIMUM FUND TRUST	97,140	0	For
John Hancock	90,063	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

5. To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their earlier death, resignation or removal: Sandra Swain, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 92,157,301WITHHELD: 224,265

Immunome, Inc.’s own tally for this item (“Elect Director: Sandra Swain, M.D.”): 92,157,301 for, 224,265 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 113,171,396 outstanding shares: 81% for, 0.2% withheld (82% of the company cast a for/withheld vote).

The 67 asset managers below cast 100% of the shares they voted on this item FOR (48,078,807 for, 0 against).

FOR 99.9%

FOR: 48,078,807 (100.0%)ABSTAIN: 14,734 (0.0%)

Largest asset managers voting on “To elect the three nominees named in the Proxy Statement to serve as Class III directors, to hold office until” at Immunome, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	13,126,857	0	For
Fidelity	10,977,814	0	For
Vanguard	8,176,818	1	For
PRIMECAP Odyssey Funds	3,867,541	0	For
BlackRock	3,035,715	0	For
State Street	2,338,299	0	For
JPMorgan	1,123,081	0	For
Charles Schwab	853,198	0	For
DRIEHAUS MUTUAL FUNDS	622,369	0	For
Principal	565,036	0	For
JANUS INVESTMENT FUND	352,024	0	For
Tema ETF Trust	301,042	0	For
TIAA	295,345	0	For
Equitable	250,719	0	For
First Trust	238,199	0	For
Hartford	133,744	0	For
RBB FUND, INC.	132,949	0	For
Lincoln Financial	123,166	0	For
Columbia Threadneedle	121,028	0	For
Victory Capital	109,472	0	For
Northwestern Mutual	108,857	0	For
QUANTITATIVE MASTER SERIES LLC	108,308	0	For
TRUST FOR PROFESSIONAL MANAGERS	101,877	0	For
OPTIMUM FUND TRUST	97,140	0	For
John Hancock	90,063	0	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

6. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 104,100,900AGAINST: 27,134

Immunome, Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accountin”): 104,100,900 for, 27,134 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 113,171,396 outstanding shares: 92% for, 0.1% against (92% of the company cast a for/against vote).

The 67 asset managers below cast 100% of the shares they voted on this item FOR (48,087,707 for, 0 against).

FOR 99.9%

FOR: 48,087,707 (100.0%)ABSTAIN: 5,834 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCA” at Immunome, Inc., 2025-2026
Asset manager	For	Vote
T. Rowe Price	13,126,857	For
Fidelity	10,977,814	For
Vanguard	8,176,819	For
PRIMECAP Odyssey Funds	3,867,541	For
BlackRock	3,035,715	For
State Street	2,338,299	For
JPMorgan	1,123,081	For
Charles Schwab	853,198	For
DRIEHAUS MUTUAL FUNDS	622,369	For
Principal	565,036	For
JANUS INVESTMENT FUND	352,024	For
Tema ETF Trust	301,042	For
TIAA	295,345	For
Equitable	250,719	For
First Trust	238,199	For
Hartford	133,744	For
RBB FUND, INC.	132,949	For
Lincoln Financial	123,166	For
Columbia Threadneedle	121,028	For
Victory Capital	109,472	For
Northwestern Mutual	108,857	For
QUANTITATIVE MASTER SERIES LLC	108,308	For
TRUST FOR PROFESSIONAL MANAGERS	101,877	For
OPTIMUM FUND TRUST	97,140	For
John Hancock	90,063	For

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

7. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTESCOMPENSATION

100% fund support · no official result

1 YEAR 91%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (7,818 for, 0 against).

FOR: 7,818 (3.4%)1 YEAR: 208,094 (90.6%)ONE YEAR: 13,800 (6.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Immunome, Inc., 2025-2026
Asset manager	For	Vote
Granahan Investment Management, LLC	0	1 Year
FORUM FUNDS II	0	One Year
ANTIPODES PARTNERS Ltd	7,818	For
Coyle Financial Counsel LLC	0	1 Year

Largest Immunome, Inc. shareholders voting in 2025-2026

Ranked by the number of Immunome, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 113,171,396 shares outstanding at the time of that meeting.

Top Immunome, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	28.69%
2	Fidelity	23.42%
3	Vanguard	7.99%
4	Redmile Group, LLC	4.72%
5	BlackRock	4.57%
6	PRIMECAP MANAGEMENT CO/CA/	4.02%
7	State Street	3.45%
8	Wellington	3.44%
9	PRIMECAP Odyssey Funds	3.42%
10	Enavate Sciences GP, LLC	3.19%

Reported Immunome, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Immunome, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	14.99%	13F
Entities affiliated with FMR LLC	11.54%	DEF14A
Entities affiliated with T. Rowe Price Investment Management, Inc.	9.41%	DEF14A
BlackRock	7.22%	13F
Vanguard Group	5.34%	13F
Entities affiliated with Redmile Group LLC	5.05%	DEF14A
Redmile Group, LLC	4.91%	13G
State Street	4.77%	13F
Clay Siegall, Ph.D.	3.28%	DEF14A
T. Rowe Price	2.53%	13F

Percentages above are of 113,171,396 shares outstanding, as reported by Immunome, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Immunome, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Immunome, Inc.'s shareholder meeting held 2026-06-09, in the 2025-2026 proxy season, 220 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,771 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Immunome, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.

Immunome, Inc. proxy season coverage: 2025-2026 (this page).